Cubist Systematic Strategies, LLC Xeris Biopharma Holdings, Inc. Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.8 - $2.69 $27,016 - $40,374	-15,009 Reduced 99.37%	95 $0
Q2 2023 Aug 14, 2023	BUY	$1.82 - $2.98 $27,489 - $45,009	15,104 New	15,104 $39,000
Q4 2022 Feb 14, 2023	SELL	$1.14 - $1.65 $7,612 - $11,018	-6,678 Reduced 45.6%	7,968 $10,000
Q3 2022 Nov 14, 2022	SELL	$1.37 - $1.93 $1,794 - $2,528	-1,310 Reduced 8.21%	14,646 $23,000
Q2 2022 Aug 15, 2022	SELL	$1.48 - $2.64 $294,949 - $526,125	-199,290 Reduced 92.59%	15,956 $25,000
Q1 2022 May 16, 2022	SELL	$2.0 - $2.87 $193,102 - $277,101	-96,551 Reduced 30.97%	215,246 $551,000
Q4 2021 Feb 14, 2022	BUY	$1.8 - $2.93 $561,234 - $913,565	311,797 New	311,797 $914,000

143

60M

148K

45.7K

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $462M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.